caa a22 4500 445308788 CHVBK 20180317142622.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1007/s00404-010-1462-9 doi (NATIONALLICENCE)springer-10.1007/s00404-010-1462-9 Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer [Elektronische Daten] [Christopher Bryant, Sanjeev Kumar, Whitney Spannuth, Jay Shah, Adnan Munkarah, Gunter Deppe, Ronald Alvarez, Robert Morris] Purpose: The goal of this study was to evaluate the outcomes and response in a cohort of patients with presumed platinum-sensitive disease who were subsequently retreated with platinum after receiving weekly bolus topotecan at the time of initial recurrence. Methods: A retrospective review of our institutional databases identified a cohort of platinum-sensitive women with recurrent ovarian and peritoneal carcinoma. Antitumor responses and toxicities were assessed for patients retreated with platinum-based chemotherapy following weekly bolus topotecan (4mg/m2). Results: Twenty-six patients (median age 63years, range 45-80years) were identified. Advanced stage (III/IV) ovarian carcinoma was most common (96%). Residual disease after primary cytoreductive surgery was less than 1cm in 65% of the cohort. Platinum retreatment was well tolerated. Grade 3 neutropenia occurred most commonly (8%) without any episodes of grade 4 myelotoxicity. Fatigue (12%) and hypersensitivity reaction (15%) were the most common non-hematologic toxicities during platinum retreatment. Of the 26 patients, 5 (19%) had a complete response, 5 (19%) had a partial response, 10 (39%) had stable disease, and 6 (23%) had progressive disease. Thirty-nine percent of patients with stable or progressive disease during weekly bolus topotecan responded to subsequent platinum retreatment. Response to platinum retreatment, treatment-free interval, and platinum-free interval was significant prognosticators for survival (P<0.05). Conclusion(s): The results of this retrospective analysis suggest that weekly bolus topotecan, as intervening non-platinum, may result in acceptable toxicities and response rates during platinum retreatment in platinum-sensitive relapsed ovarian or peritoneal carcinoma. Springer-Verlag, 2010 Recurrent ovarian cancer nationallicence Platinum-free interval nationallicence Weekly bolus topotecan nationallicence Platinum retreatment nationallicence Platinum-sensitive nationallicence Non-platinum nationallicence Bryant Christopher Wayne State University, Barbara Ann Karmanos Cancer Institute, Harper Professional Building, 4160 John R Street, Suite 2126, 48201, Detroit, MI, USA aut Kumar Sanjeev Wayne State University, Barbara Ann Karmanos Cancer Institute, Harper Professional Building, 4160 John R Street, Suite 2126, 48201, Detroit, MI, USA aut Spannuth Whitney University of Alabama at Birmingham, Birmingham, AL, USA aut Shah Jay Wayne State University, Barbara Ann Karmanos Cancer Institute, Harper Professional Building, 4160 John R Street, Suite 2126, 48201, Detroit, MI, USA aut Munkarah Adnan Henry Ford Health System, Detroit, MI, USA aut Deppe Gunter Wayne State University, Barbara Ann Karmanos Cancer Institute, Harper Professional Building, 4160 John R Street, Suite 2126, 48201, Detroit, MI, USA aut Alvarez Ronald University of Alabama at Birmingham, Birmingham, AL, USA aut Morris Robert Wayne State University, Barbara Ann Karmanos Cancer Institute, Harper Professional Building, 4160 John R Street, Suite 2126, 48201, Detroit, MI, USA aut Archives of Gynecology and Obstetrics Springer-Verlag 283/2(2011-02-01), 361-367 0932-0067 283:2<361 2011 283 404 https://doi.org/10.1007/s00404-010-1462-9 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00404-010-1462-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Bryant Christopher Wayne State University, Barbara Ann Karmanos Cancer Institute, Harper Professional Building, 4160 John R Street, Suite 2126, 48201, Detroit, MI, USA aut NATIONALLICENCE 700 1- Kumar Sanjeev Wayne State University, Barbara Ann Karmanos Cancer Institute, Harper Professional Building, 4160 John R Street, Suite 2126, 48201, Detroit, MI, USA aut NATIONALLICENCE 700 1- Spannuth Whitney University of Alabama at Birmingham, Birmingham, AL, USA aut NATIONALLICENCE 700 1- Shah Jay Wayne State University, Barbara Ann Karmanos Cancer Institute, Harper Professional Building, 4160 John R Street, Suite 2126, 48201, Detroit, MI, USA aut NATIONALLICENCE 700 1- Munkarah Adnan Henry Ford Health System, Detroit, MI, USA aut NATIONALLICENCE 700 1- Deppe Gunter Wayne State University, Barbara Ann Karmanos Cancer Institute, Harper Professional Building, 4160 John R Street, Suite 2126, 48201, Detroit, MI, USA aut NATIONALLICENCE 700 1- Alvarez Ronald University of Alabama at Birmingham, Birmingham, AL, USA aut NATIONALLICENCE 700 1- Morris Robert Wayne State University, Barbara Ann Karmanos Cancer Institute, Harper Professional Building, 4160 John R Street, Suite 2126, 48201, Detroit, MI, USA aut NATIONALLICENCE 773 0- Archives of Gynecology and Obstetrics Springer-Verlag 283/2(2011-02-01), 361-367 0932-0067 283:2<361 2011 283 404 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer